Celcuity Inc. (CELC) · Sep 30, 2026 · Other events
U.S. launch — Commercial availability follows July 14 FDA approval and late-Q3 launch plan
Celcuity’s REVTORPYK launch is now live as planned for PIK3CA wild-type breast cancer, shifting the story from FDA approval to market uptake.
Celcuity is transitioning from a newly approved biotech into a commercial-stage company: REVTORPYK is its first FDA-approved product, while VIKTORIA-2 remains the main expansion program into first-line breast cancer treatment and the company is pursuing a broader PIK3CA-mutated label. This filing completes the regulatory-to-commercial handoff. REVTORPYK is now available in the United States for eligible patients with HR+/HER2- advanced breast cancer whose tumors lack a detected PIK3CA mutation after progression on endocrine therapy.
The event is important operationally, but not a surprise versus expectations. The FDA approval was already announced on July 14, 2026, and management had said commercial launch was targeted for late third-quarter 2026, so September 30 is essentially the expected launch window rather than a new regulatory win. 〔0〕 The business question now changes from approval risk to commercial adoption. The company has launched patient-support and reimbursement assistance, which may reduce access friction, but the filing provides no pricing, prescription, payer-coverage, or revenue data yet.
The product has a differentiated efficacy story, but commercialization still carries a tolerability burden. In the PIK3CA wild-type cohort, the company cites 76% and 67% reductions in the risk of progression or death for the triplet and doublet versus fulvestrant, respectively. However, the label highlights frequent stomatitis, rash, and increased fasting glucose, including Grade 3 stomatitis in 22% of triplet-treated patients and 12% of doublet-treated patients. Those adverse effects could influence physician selection, monitoring, and persistence even though the filing does not yet show real-world uptake.
The next value-creating expansion remains outside today’s approved population. Celcuity submitted an sNDA in August for PIK3CA-mutated disease; approval would broaden the addressable population beyond the current wild-type-only label. Bottom line: This is a meaningful execution milestone that puts Celcuity’s first product into the market, but it mainly confirms a previously telegraphed launch. The next proof point is commercial uptake, not another approval headline.
First commercial sales update, likely with next quarterly results
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!